Ernest Loumaye, MD, PhD, OB/GYN has extensive experience in pharma product development and the management of biopharmaceutical companies..
After a brief academic career at Louvain University Hospital, he joined Serono as Head of Clinical Development for Reproductive Health (Geneva and Boston). He contributed actively to the worldwide registration of three important biotechnology products. In 2003, Ernest joined Ipsen in Paris as Vice President, Medical Sciences. In 2006, Ernest co-founded PregLem, a Swiss based specialty biopharmaceutical company. As CEO, he led the company up to the successful European registration of Esmya®, its lead product. The company was acquired by Gedeon Richter Plc. in 2010.
In 2012, Ernest co-founded ObsEva and since then has served as the CEO of the company and as Board Member. Based in Geneva, ObsEva SA (NASDAQ: OBSV / SIX: OBSN) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.
Ernest Loumaye was a visiting Professor of Reproductive Endocrinology at Louvain University, Brussels from 2002 to 2010, where he held a full time clinical and academic position until 1991.
Ernest holds MD, PhD degrees, with a specialization in Obstetrics and Gynaecology from Louvain University, Belgium. He was a research fellow at the National Institute of Child Health and Human Development in the US and is the author of over 90 publications in peer-reviewed journals.
He also currently serves as a Board Member for AVA in Zurich a FEMTECH company.